Pi Therapeutics

About:

Pi Therapeutics is a Cancer treatment company

Top Investors: Pontifax, Quark Venture, Arkin Bio Ventures, GF Securities, RMGP Biopharma Investment Fund

Description:

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

Total Funding Amount:

$19.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ness Ziona, HaMerkaz, Israel

Founded Date:

2015-01-01

Founders:

Ori Kalid

Number of Employees:

1-10

Last Funding Date:

2019-05-29

IPO Status:

Private

Industries: